Paraneoplastic Syndromes: Clinical Trials

98 trials for Paraneoplastic Syndromes, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed, 21 recruiting, 12 active not recruiting, 8 terminated. 98 Phase 3, 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 398Completed 46, Recruiting 21, Active not recruiting 12, Terminated 8, Unknown 7, Enrolling by invitation 2, Not yet recruiting 1, Withdrawn 1
Phase 214Recruiting 6, Unknown 2, Active not recruiting 1, Completed 1, Enrolling by invitation 1, Not yet recruiting 1, Terminated 1, Withdrawn 1

Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes

Trials (filtered) newest first · largest first

All 98 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab - Ocular Myasthenia Gravis
Phase 3RecruitingUCB Biopharma SRL1002026-09-162026-11-06
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Ravulizumab - Generalized Myasthenia Gravis, gMG
Phase 3RecruitingAlexion Pharmaceuticals, Inc.202026-07-272026-10-21
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Claseprubart, Placebo - Myasthenia Gravis, Generalized
Phase 3RecruitingDianthus Therapeutics1952026-06-292026-10-30
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab, Placebo - Ocular Myasthenia Gravis
Phase 3RecruitingUCB Biopharma SRL1202026-05-272026-11-06
Zilucoplan for Severe gMG Exacerbations
Zilucoplan® - Generalized Myasthenia Gravis (gMG)
Phase 3RecruitingMiriam Freimer152026-01-202026-08-28
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Telitacicept, Placebo - Myasthenia Gravis, Ocular
Phase 3RecruitingRemeGen Co., Ltd.1202026-01-132026-04-09
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Nipocalimab, Efgartigimod - Myasthenia Gravis
Phase 3RecruitingJanssen Research & Development, LLC1152026-01-052026-11-03
Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
High-dose corticosteroids (HDCS), High-dose corticosteroids (HDCS) and PLEX - Optic Neuritis, Myelitis
Phase 3RecruitingMayo Clinic3822025-07-112026-09-24
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
IMVT-1402, Placebo - Generalized Myasthenia Gravis
Phase 3RecruitingImmunovant Sciences GmbH2312025-05-272026-11-13
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
Decartes-08, Placebo Drug - Myasthaenia Gravis
Phase 3Active not recruitingCartesian Therapeutics1282025-05-062026-09-01
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
immediate treatment with corticosteroids, addition of rituximab if recurrence - Ocular Myasthenia Gravis
Phase 3RecruitingFondation Ophtalmologique Adolphe de Rothschild1282025-04-292026-01-21
Blinatumomab for Treatment of Refractory Myasthenia Gravis
Blinatumomab - Myasthenia Gravis
Phase 2 / Phase 3Not yet recruitingDa, Yuwei, M.D.22025-04-012025-03-25
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label) - Generalized Myasthenia Gravis
Phase 3Active not recruitingNovartis Pharmaceuticals1802025-02-072026-09-28
Efgartigimod in IVIG Dependent Myasthenia Gravis Patients
efgartigimod administration - Myasthaenia Gravis
Phase 3RecruitingClinique Neuro-Outaouais302025-02-062026-10-22
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
Eculizumab - Generalized Myasthenia Gravis (gMG), Refractory gMG
Phase 3CompletedAlexion Pharmaceuticals, Inc.152025-01-062026-01-15
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Zilucoplan - Generalized Myasthenia Gravis
Phase 3Enrolling by invitationUCB Biopharma SRL82024-11-192026-10-02
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Gefurulimab - Generalized Myasthenia Gravis, gMG
Phase 3RecruitingAlexion Pharmaceuticals, Inc.122024-11-132026-04-01
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Ofatumumab combined with daratumumab, Ofatumumab, Repeated intravenous immunoglobulin/plasma exchange therapy - Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Phase 3RecruitingThe First People's Hospital of Changzhou2002024-11-082026-06-09
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Zilucoplan - Generalized Myasthenia Gravis
Phase 2 / Phase 3RecruitingUCB Biopharma SRL82024-10-162026-11-05
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
rozanolixizumab - Generalized Myasthenia Gravis
Phase 3Active not recruitingUCB Biopharma SRL132024-10-082026-11-06

Showing 20 of 98. Sign in to see all of them.

Narrower conditions

Myasthenia Gravis (79)  ·  Myelitis, Transverse (8)  ·  Neuromyelitis Optica (6)  ·  ACTH Syndrome, Ectopic (5)  ·  Cushing Syndrome (5)  ·  Optic Neuritis (5)  ·  Demyelinating Diseases (4)  ·  Pituitary ACTH Hypersecretion (4)  ·  Recurrence (4)  ·  Autoimmune Diseases (3)  ·  Pituitary Diseases (3)  ·  Adrenal Cortex Neoplasms (2)  ·  Choristoma (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Hirsutism (2)

Broader conditions

Neoplasms (98)  ·  Nervous System Diseases (95)  ·  Neoplasms by Site (93)  ·  Nervous System Neoplasms (91)  ·  Neurodegenerative Diseases (91)  ·  Paraneoplastic Syndromes, Nervous System (91)  ·  Immune System Diseases (90)  ·  Autoimmune Diseases of the Nervous System (89)  ·  Autoimmune Diseases (87)  ·  Neuromuscular Diseases (81)  ·  Neuromuscular Junction Diseases (81)  ·  Central Nervous System Diseases (14)  ·  Neuroinflammatory Diseases (9)  ·  Pathological Conditions, Signs and Symptoms (9)

Interventions

rozanolixizumab (8)  ·  eculizumab (7)  ·  zilucoplan (7)  ·  Amifampridine (5)  ·  efgartigimod alfa (5)  ·  Rituximab (4)  ·  ravulizumab (4)  ·  Corlux (3)  ·  Mifepristone (3)  ·  Tacrolimus (3)  ·  telitacicept (3)  ·  Adrenal Cortex Hormones (2)  ·  Cyclophosphamide (2)  ·  HBM9161 (2)  ·  Immunoglobulins, Intravenous (2)

Sponsors

Alexion Pharmaceuticals, Inc. (13)  ·  UCB Biopharma SRL (13)  ·  argenx (10)  ·  Corcept Therapeutics (5)  ·  Catalyst Pharmaceuticals, Inc. (4)  ·  Astellas Pharma Inc (3)  ·  Janssen Research & Development, LLC (3)  ·  AstraZeneca (2)  ·  First Affiliated Hospital, Sun Yat-Sen University (2)  ·  Harbour BioMed (Guangzhou) Co. Ltd. (2)  ·  Hoffmann-La Roche (2)  ·  Immunovant Sciences GmbH (2)  ·  Novartis Pharmaceuticals (2)  ·  RemeGen Co., Ltd. (2)  ·  University Health Network, Toronto (2)

Countries

United States (64)  ·  Italy (46)  ·  Poland (44)  ·  Spain (43)  ·  Japan (42)  ·  Canada (41)  ·  Germany (40)  ·  France (32)  ·  United Kingdom (32)  ·  China (26)  ·  Denmark (22)  ·  Georgia (21)  ·  Netherlands (20)  ·  Belgium (19)  ·  South Korea (19)

Top investigators

Andreas Moraitis, MD (2)  ·  Gil Wolfe, MD (2)  ·  Renato Mantegazza, MD (2)  ·  Vera Bril, MD (2)  ·  Antonio Guglietta, MD (1)  ·  Brian G. Weinshenker (1)  ·  Charles W Gorodetzky, MD, PhD (1)  ·  Chongbo Zhao (1)

Results publications

PMID 37059507, PMID 42388397, PMID 25013998, PMID 26507877, PMID 30905021, PMID 32189108, PMID 32426038, PMID 32700461, PMID 33229455, PMID 33329303, PMID 33676197, PMID 34146511, PMID 34498507, PMID 34590717, PMID 37059508, PMID 38400914, PMID 39314260, PMID 40105996, PMID 40504283, PMID 42855714, PMID 18567886, PMID 18675464, PMID 21784757, PMID 22047648, PMID 22466348, PMID 23278584, PMID 23970725, PMID 25032816, PMID 26009577, PMID 27509100, PMID 28639937, PMID 28861121, PMID 29066163, PMID 30692052, PMID 30767274, PMID 31050279, PMID 31115842, PMID 31698177, PMID 32611638, PMID 33219142, PMID 33310418, PMID 33796147, PMID 34795626, PMID 34803867, PMID 35058882, PMID 36121672, PMID 36852670, PMID 36890354, PMID 37103755, PMID 38099334

NIH funding

2023 (8), 2019 (4), 2018 (3), 2025 (3), 2014 (1), 2016 (1), 2017 (1), U01NS042685 (1)